Original Articles

Journal of General Internal Medicine

, Volume 21, Issue 7, pp 694-697

First online:

Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists

The tortoise and the hare revisited
  • Brian D. De SmetAffiliated withDepartment of Pharmacy Services, University of Michigan Hospitals and Health CentersDepartment of Clinical Sciences, College of Pharmacy, University of Michigan
  • , A. Mark FendrickAffiliated withDepartment of Internal Medicine, School of Medicine, University of MichiganDepartment of Health Management & Policy, School of Public Health, University of Michigan
  • , James G. StevensonAffiliated withDepartment of Pharmacy Services, University of Michigan Hospitals and Health CentersDepartment of Clinical Sciences, College of Pharmacy, University of Michigan
  • , Steven J. BernsteinAffiliated withDepartment of Internal Medicine, School of Medicine, University of MichiganDepartment of Health Management & Policy, School of Public Health, University of MichiganCenter for Practice Management and Outcomes Research, VA Ann Arbor Healthcare System Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

OBJECTIVES: To compare prescribing trends and appropriateness of use of traditional and cyclooxygenase-2 selective (COX-2) nonsteroidal anti-inflammatory drugs (NSAIDs) by primary care physicians (PCPs) and specialists.

DESIGN: Retrospective cohort study.

PATIENTS: One thousand five hundred and seventy-six adult patients continuously enrolled for at least 1 year with an independent practice association of a University-associated managed care plan who were started on a traditional NSAID or a COX-2 inhibitor from 1999 to 2002 and received at least 3 separate medication fills.

MEASUREMENTS: Physician specialty was identified from office visits. Appropriateness of utilization was based on gastrointestinal risk characteristics.

RESULTS: Primary care patients were younger and less likely to have comorbid conditions. Despite similar GI risk, COX-2 use among patients seen by PCPs was half that of patients seen by specialists (21% vs 44%, P<.001). While PCPs overused cyclooxygenase-2-specific inhibitors (COX-2s) less often than specialists (19% vs 41%, P<.001), they also tended to underuse COX-2s in patients who were at increased GI risk (46% vs 32%, P=.063). This represents a 3-fold and 8-fold difference in overuse versus underuse for PCPs and specialists, respectively.

CONCLUSIONS: Using COX-2s as a model for physician adoption of new therapeutic agents, specialists were more likely to use these new medications for patients likely to benefit but were also significantly more likely to use them for patients without a clear indication. This study demonstrates the tension between appropriate adoption of innovative therapies for those individuals who would benefit from their use and those individuals who would receive no added clinical benefit but would incur added cost and be placed at increased risk.

Key words

primary care appropriateness COX-2 practice patterns specialist